Article
RCAN1-mediated calcineurin inhibition as a target for cancer therapy
18 Jun 2022
Abstract excerpt
Cancer is the leading cause of mortality worldwide. Regulator of calcineurin 1 (RCAN1), as a patent endogenous inhibitor of calcineurin, plays crucial roles in the pathogenesis of cancers. Except for hypopharyngeal and laryngopharynx cancer, high expression of RCAN1 inhibits tumor progression. Molecular antitumor functions of RCAN1 are largely dependent on calcineurin. In this review, we highlight current...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
